GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT01539512
- Locations
- 🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸UCLA, Santa Monica, California, United States
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 161
- Registration Number
- NCT01539291
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Dorset County Hospital, Dorchester, United Kingdom
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT01533259
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸Anthony Mills MD, Inc, Los Angeles, California, United States
🇺🇸Peter J. Ruane, MD, Inc., Los Angeles, California, United States
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 134
- Registration Number
- NCT01522651
- Locations
- 🇬🇧
Investigational Site, London, England, United Kingdom
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
- Conditions
- Interventions
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01510561
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
🇺🇸Goshen Center for Cancer Care, Goshen, Indiana, United States
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 279
- Registration Number
- NCT01497899
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸Gary J. Richmond,M.D.,P.A., Fort Lauderdale, Florida, United States
🇺🇸Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
Phase 3 Study of Sofosbuvir and Ribavirin
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 527
- Registration Number
- NCT01497366
- Locations
- 🇺🇸
Peter J. Ruane, M.D. Inc., Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Inc., Atlanta, Georgia, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
Open-Label Hepatic Impairment Study
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01497327
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 439
- Registration Number
- NCT01495702
- Locations
- 🇺🇸
Anthony Mills MD Inc, Los Angeles, California, United States
🇺🇸Atlanta ID Group, PC, Atlanta, Georgia, United States
🇺🇸Saint Michael's Medical Center, Newark, New Jersey, United States
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 431
- Registration Number
- NCT01494987
- Locations
- 🇺🇸
Clinical Research Advantage/Desert Clinical Research, LLC, Mesa, Arizona, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States